Analyst Price Targets — BHVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 3, 2026 7:43 pm | Marc Goodman | Leerink Partners | $15.00 | $10.67 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates |
| February 5, 2026 9:18 pm | — | Goldman Sachs | $23.00 | $10.76 | TheFly | Biohaven initiated with a Buy at Goldman Sachs |
| January 21, 2026 10:09 am | — | RBC Capital | $22.00 | $12.68 | TheFly | Biohaven upgraded to Outperform from Sector Perform at RBC Capital |
| December 3, 2025 11:08 am | — | H.C. Wainwright | $11.00 | $8.83 | TheFly | Biohaven downgraded to Neutral from Buy at H.C. Wainwright |
| November 26, 2025 9:57 am | — | UBS | $11.00 | $9.24 | TheFly | Biohaven downgraded to Neutral from Buy at UBS |
| November 18, 2025 2:26 pm | — | Morgan Stanley | $26.00 | $9.45 | TheFly | Biohaven price target lowered to $26 from $54 at Morgan Stanley |
| November 5, 2025 11:09 am | Brian Skorney | Robert W. Baird | $42.00 | $13.95 | StreetInsider | Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird |
| March 20, 2025 7:39 am | — | Deutsche Bank | $60.00 | $28.18 | TheFly | Immunovant data positive for Biohaven, says Deutsche Bank |
| March 4, 2025 12:24 pm | — | Bernstein | $57.00 | $31.37 | TheFly | Biohaven price target lowered to $57 from $73 at Bernstein |
| December 4, 2024 1:59 pm | Leonid Timashev | RBC Capital | $61.00 | $46.58 | StreetInsider | Biohaven Pharmaceutical Holding (BHVN) PT Raised to $61 at RBC Capital |
Latest News for BHVN
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity: Inflammation and Immunology: Graves' Disease: First-in-patient clinical experience with IgG MoDE…
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Goldman initiated a buy rating on Biohaven targeting its IgAN treatment in an over $40B U.S. market.
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of the tech trade continues to gain strength. Toss in the weakness in cryptocurrencies, along with a renewed skepticism towards the asset, and the... Here Are Friday's Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHVN.
U.S. House Trading
No House trades found for BHVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.